Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Debt to Equity (2017 - 2025)

United Therapeutics' Debt to Equity history spans 14 years, with the latest figure at $0.03 for Q1 2025.

  • On a quarterly basis, Debt to Equity fell 73.86% to $0.03 in Q1 2025 year-over-year; TTM through Mar 2025 was $0.03, a 73.86% decrease, with the full-year FY2024 number at $0.05, down 60.2% from a year prior.
  • Debt to Equity hit $0.03 in Q1 2025 for United Therapeutics, down from $0.05 in the prior quarter.
  • Over the last five years, Debt to Equity for UTHR hit a ceiling of $0.23 in Q1 2021 and a floor of $0.03 in Q1 2025.
  • Historically, Debt to Equity has averaged $0.15 across 5 years, with a median of $0.16 in 2023.
  • Biggest five-year swings in Debt to Equity: dropped 14.24% in 2021 and later plummeted 73.86% in 2025.
  • Tracing UTHR's Debt to Equity over 5 years: stood at $0.2 in 2021, then dropped by 17.47% to $0.17 in 2022, then decreased by 29.87% to $0.12 in 2023, then crashed by 60.2% to $0.05 in 2024, then plummeted by 36.89% to $0.03 in 2025.
  • Business Quant data shows Debt to Equity for UTHR at $0.03 in Q1 2025, $0.05 in Q4 2024, and $0.07 in Q3 2024.